STOCK TITAN

PTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SOUTH PLAINFIELD, N.J., Nov. 19, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1st at 11:45 a.m. ET.

The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.

About PTC Therapeutics, Inc.

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.

FOR MORE INFORMATION PLEASE CONTACT:


Media: 

Investors:

Jane Baj 

Lisa Hayes

+1 (908) 912-9167

+1 (732) 354-8687

jbaj@ptcbio.com

lhayes@ptcbio.com 

Cision View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference-301174099.html

SOURCE PTC Therapeutics, Inc.

PTC Therapeutics Inc

NASDAQ:PTCT

PTCT Rankings

PTCT Latest News

PTCT Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
US
South Plainfield

About PTCT

ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.